66,358 Shares in RxSight, Inc. (NASDAQ:RXST) Acquired by Lighthouse Investment Partners LLC

Lighthouse Investment Partners LLC acquired a new position in shares of RxSight, Inc. (NASDAQ:RXST) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 66,358 shares of the company’s stock, valued at approximately $3,993,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Precision Wealth Strategies LLC acquired a new stake in RxSight in the 4th quarter worth about $287,000. Charles Schwab Investment Management Inc. boosted its stake in shares of RxSight by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 190,337 shares of the company’s stock valued at $7,674,000 after buying an additional 8,003 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in RxSight during the 4th quarter valued at $642,000. Clear Rock Advisors LLC acquired a new position in RxSight in the fourth quarter worth about $172,000. Finally, Seven Eight Capital LP acquired a new position in RxSight in the fourth quarter worth $1,085,000. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RXST has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. BTIG Research raised their price objective on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Stifel Nicolaus reduced their target price on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Oppenheimer dropped their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Finally, Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, RxSight currently has an average rating of “Buy” and an average price target of $60.14.

RxSight Stock Performance

RxSight stock opened at $48.54 on Friday. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54. The business’s fifty day moving average is $51.15 and its two-hundred day moving average is $53.82. The firm has a market cap of $1.80 billion, a P/E ratio of -38.52 and a beta of 1.22.

RxSight (NASDAQ:RXST) last issued its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The company had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same quarter last year, the firm earned ($0.40) EPS. The company’s revenue for the quarter was up 67.6% on a year-over-year basis. On average, equities research analysts predict that RxSight, Inc. will post -0.81 earnings per share for the current year.

Insider Activity at RxSight

In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at $816,906.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total value of $163,277.00. Following the sale, the insider now owns 42,246 shares in the company, valued at approximately $2,225,096.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Shelley B. Thunen sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares in the company, valued at approximately $816,906.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,200 shares of company stock worth $1,267,516. 9.36% of the stock is currently owned by company insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.